NY-ESO-1 reactive TCR retroviral vector transduced autologous PBL

BIOLOGICAL3 trials

Sponsors

Jonsson Comprehensive Cancer Center

Conditions

Adult Solid NeoplasmChildhood Solid NeoplasmMalignant NeoplasmMetastatic NeoplasmUnspecified Adult Solid Tumor, Protocol Specific

Phase 1

Gene-Modified T Cells, Vaccine Therapy, and Ipilimumab in Treating Patients With Locally Advanced or Metastatic Malignancies

TerminatedNCT02070406

Jonsson Comprehensive Cancer CenterUnspecified Adult Solid Tumor, Protocol Specific

Start: 2014-07-17End: 2018-12-18Updated: 2019-02-28

Gene-Modified T Cells, Vaccine Therapy, and Nivolumab in Treating Patients With Stage IV or Locally Advanced Solid Tumors Expressing NY-ESO-1

CompletedNCT02775292

Jonsson Comprehensive Cancer CenterAdult Solid Neoplasm, Childhood Solid Neoplasm, Metastatic Neoplasm

Start: 2017-01-03End: 2019-04-08Updated: 2025-07-30

Phase 2

Gene and Vaccine Therapy in Treating Patients With Advanced Malignancies

Active, not recruitingNCT01697527

Jonsson Comprehensive Cancer CenterMalignant Neoplasm

Start: 2012-11-02End: 2027-11-02Updated: 2025-11-24

Related Papers

Immunotherapy resistance driven by loss of NY-ESO-1 expression in response to transgenic adoptive cellular therapy with PD-1 blockade

Journal for ImmunoTherapy of Cancer2023-05-0117 citations

Abstract 914: Preinfusion polyfunctional profiles and cytokine secretion activity of transgenic TCR-T cells, and serum cytokine profiles, are associated with clinical outcomes in sarcoma and melanoma

Cancer Research2023-04-04

A Pilot Trial of the Combination of Transgenic NY-ESO-1–reactive Adoptive Cellular Therapy with Dendritic Cell Vaccination with or without Ipilimumab

Clinical Cancer Research2018-12-2091 citations

Abstract CT008: A pilot trial of the combination of transgenic NY-ESO-1-reactive adoptive cellular therapy with dendritic cell vaccination with or without ipilimumab in patients with sarcoma and melanoma

Cancer Research2018-07-013 citations